Phase III Results Show Moderna Could Challenge In Blockbuster RSV Vaccine Market
First Data Cut Shows 83% Efficacy Against Infection
Moderna has moved fast to catch up with GSK and Pfizer, but will still be up to a year behind in reaching the market in the burgeoning RSV market.
